/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
Abbott Laboratories (ABT), the global healthcare titan, announced on Dec. 22 that the U.S. Food and Drug Administration (FDA) has approved its Volt™ PFA System for treating atrial fibrillation (AFib). Abbott will soon begin commercial PFA procedures in the U.S. and continue expanding European sites, building on Volt’s CE Mark approval earlier this year and accelerating global market penetration.
AFib presents a rapidly growing clinical and economic burden. Around 12 million Americans aged over 65 currently live with AFib, and this population is expected to double over the next 20 years. Patients face a fivefold higher stroke risk, underscoring the urgency for scalable, effective treatment solutions.
